Levetiracetam

Generic Name
Levetiracetam
Brand Names
Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
Drug Type
Small Molecule
Chemical Formula
C8H14N2O2
CAS Number
102767-28-2
Unique Ingredient Identifier
44YRR34555
Background

Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...

Indication

Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...

Associated Conditions
Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
Associated Therapies
-
Clinical Trials
Related News

Levetiracetam for Painful Polyneuropathy

Phase 4
Completed
Conditions
Painful Polyneuropathy
First Posted Date
2006-02-03
Last Posted Date
2009-12-18
Lead Sponsor
Odense University Hospital
Target Recruit Count
40
Registration Number
NCT00286260
Locations
🇩🇰

Department of Neurology, Odense University Hospital, Odense C, Denmark

Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

Phase 3
Completed
Conditions
Panic Disorder
Interventions
Drug: levetiracetam
First Posted Date
2006-01-19
Last Posted Date
2011-12-13
Lead Sponsor
Lindner Center of HOPE
Target Recruit Count
15
Registration Number
NCT00279617
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

Phase 4
Completed
Conditions
Body Dysmorphic Disorder
Interventions
Drug: Levetiracetam
First Posted Date
2005-12-14
Last Posted Date
2019-08-29
Lead Sponsor
Butler Hospital
Target Recruit Count
17
Registration Number
NCT00265109
Locations
🇺🇸

Rhode Island Hospital Body Dysmorphic Disorder Program, Providence, Rhode Island, United States

Levetiracetam for Treatment of Pain Associated With Fibromyalgia

Not Applicable
Completed
Conditions
Fibromyalgia
Interventions
Drug: Placebo
Drug: Levetiracetam
First Posted Date
2005-11-16
Last Posted Date
2013-05-13
Lead Sponsor
University of California, San Francisco
Target Recruit Count
66
Registration Number
NCT00254657
Locations
🇺🇸

UCSF, San Francisco, California, United States

Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury

Phase 4
Completed
Conditions
Injuries, Spinal Cord
Pain
Interventions
Drug: Levetiracetam
First Posted Date
2005-11-15
Last Posted Date
2009-08-20
Lead Sponsor
Danish Pain Research Center
Target Recruit Count
36
Registration Number
NCT00252954
Locations
🇩🇰

Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Clinic for Spinal Cord Injuries, Rigshospitalet, Hornbaek, Denmark

🇩🇰

The Spinal Cord Unit, Dept of Rheumatology, Viborg, Denmark

Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.

Phase 4
Completed
Conditions
Epilepsy, Partial
First Posted Date
2005-10-28
Last Posted Date
2013-11-26
Lead Sponsor
UCB Pharma
Target Recruit Count
40
Registration Number
NCT00245713

Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Levetiracetam
Drug: Lamotrigine
First Posted Date
2005-10-20
Last Posted Date
2012-05-09
Lead Sponsor
Philipps University Marburg Medical Center
Target Recruit Count
409
Registration Number
NCT00242606
Locations
🇩🇪

Philipps University Marburg Medical Center, Department of Neurology, Marburg, Germany

Second-Line Treatment Choice for Epilepsy

First Posted Date
2005-09-21
Last Posted Date
2006-09-12
Lead Sponsor
Dutch Epilepsy Clinics Foundation
Target Recruit Count
60
Registration Number
NCT00208520
Locations
🇳🇱

Dutch Epilepsy Clinics Foundation, Zwolle, Netherlands

A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

First Posted Date
2005-09-20
Last Posted Date
2011-08-11
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
31
Registration Number
NCT00203216
Locations
🇺🇸

Jefferson Headache Center, Philadelphia, Pennsylvania, United States

Levetiracetam for Benign Rolandic Epilepsy

Phase 4
Completed
Conditions
Epilepsy
First Posted Date
2005-09-16
Last Posted Date
2009-03-27
Lead Sponsor
Johns Hopkins University
Target Recruit Count
6
Registration Number
NCT00181116
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy